Mutation in the DNA-binding domain of the EWS-Oct-4 oncogene results in dominant negative activity that interferes with EWS-Oct-4-mediated transactivation

International Journal of Cancer

Volumn 124, Issue 10, 2009, Pages 2312-2322

  Kim, Sol ^a   Lee, Jungwoon ^a   Ja, Young Kim ^a   Lim, Bobae ^a   Shin, Eung Kyun ^a   Han, Yong Mahn ^b   Kim, Sung Su ^c   Song, Jin Ho ^c   Kim, Jungho ^a  

^a Sogang University   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^c Chung Ang University   (South Korea)

Author keywords

Bone and soft tissue tumors; Chromosomal translocation; Dominant negative; EWS OcT 4; Self association; Transactivation; Transformation

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4; RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR POU; DNA; PRIMER DNA;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DNA BINDING; GEL MOBILITY SHIFT ASSAY; GENE MAPPING; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MUTANT; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; TRANSACTIVATION; TRANSCRIPTION INITIATION; WILD TYPE; CHROMOSOME 22; CHROMOSOME 6; DOMINANT GENE; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; SITE DIRECTED MUTAGENESIS;

BASE SEQUENCE; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 6; DNA; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENES, DOMINANT; HUMANS; MUTAGENESIS, SITE-DIRECTED; OCTAMER TRANSCRIPTION FACTOR-3; ONCOGENES; RNA-BINDING PROTEIN EWS; TRANSCRIPTIONAL ACTIVATION;

EID: 64249141070     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24228     Document Type: Article

References (47)

1. Yamaguchi S, Yamazaki Y, Ishikawa Y, Kawaguchi N, Mukai H, Nakamura T. EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12). Genes Chromosomes Cancer 2005;43:217-22.
2. Lee J, Kim JY, Kang IY, Kim HK, Han YM, Kim J. The EWS-Oct-4 fusion gene encodes a transforming gene. Biochem J 2007;406:519-26.
3. Bertolotti A, Melot T, Acker J, Vigneron M, Delattre O, Tora L. EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family EWS and h TAFII68, and subunits of TFIID and RNA polymerase II complexes. Mol Cell Biol 1998;18:1489-97.
4. Kim J, Pelletier J. Molecular genetics of chromosome translocations involving EWS and related family members. Physiol Genomics 1999;1:127-38.
5. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5.
6. Araya N, Hirota K, Shimamoto Y, Miyagishi M, Yoshida E, Ishida J, Kaneko S, Kaneko M, Nakajima T, Fukamizu A. Cooperative interaction of EWS with CREB-binding protein selectively activates hepatocyte nuclear factor 4-mediated transcription. J Biol Chem 2003;278:5427-32.
7. Gascoyne DM, Thomas GR, Latchman DS. The effects of Brn-3a on neuronal differentiation and apoptosis are differentially modulated by EWS and its oncogenic derivative EWS/Fli-1. Oncogene 2004;23:3830-40.
8. Thomas GR, Latchman DS. The pro-oncoprotein EWS (Ewing's Sarcoma protein) interacts with the Brn-3a POU transcription factor and inhibits its ability to activate transcription. Cancer Biol Ther 2002;1:428-32.
9. Lee J, Rhee BK, Bae GY, Han YM, Kim J. Stimulation of Oct-4 activity by Ewing's sarcoma protein. Stem Cells 2005;23:738-51.
10. Rossow KL, Janknecht R. The Ewing's sarcoma gene product functions as a transcriptional activator. Cancer Res 2001;61:2690-5.
11. Li H, Watford W, Li C, Parmelee A, Bryant MA, Deng C, O'Shea J, Lee SB. Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development. J Clin Invest 2007;117:1314-23.
12. Azuma M, Embree LJ, Sabaawy H, Hickstein DD Ewing sarcoma protein ewsr1 maintains mitotic integrity and proneural cell survival in the zebrafish embryo. PLoS One 2007;2:e979.
13. Scholer HR, Dressler GR, Balling R, Rohdewohld H, Gruss P. Oct-4: a germline-specific transcription factor mapping to the mouse t-complex. EMBO J 1990;9:2185-95.
14. Okamoto K, Okazawa H, Okuda A, Sakai M, Muramatsu M, Hamada H. A novel octamer binding transcription factor is differentially expressed in mouse embryonic cells. Cell 1990;60:461-72.
15. Rosner MH, Vigano MA, Ozato K, Timmons PM, Poirier F, Rigby PW, Staudt LM. A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. Nature 1990;345:686-92.
16. Goto T, Adjaye J, Rodeck CH, Monk M. Identification of genes expressed in human primordial germ cells at the time of entry of the female germ line into meiosis. Mol Hum Reprod 1999;5:851-60.
17. Hansis C, Grifo JA, Krey LC. Oct-4 expression in inner cell mass and trophectoderm of human blastocysts. Mol Hum Reprod 2000;6:999-1004.
18. Burdon T, Smith A, Savatier P. Signalling, cell cycle and pluripotency in embryonic stem cells. Trends Cell Biol 2002;12:432-8.
19. Herr W, Cleary MA. The POU domain: versatility in transcriptional regulation by a flexible two-in-one DNA-binding domain. Genes Dev 1995;9:1679-93.
20. Pesce M, Scholer HR. Oct-4: gatekeeper in the beginnings of mammalian development. Stem Cells 2001;19:271-8.
21. Ovitt CE, Scholer HR. The molecular biology of Oct-4 in the early mouse embryo. Mol Hum Reprod 1998;4:1021-31.
22. Gidekel S, Pizov G, Bergman Y, Pikarsky E. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 2003;4:361-70.
23. Looijenga LH, Stoop H, de Leeuw HP, de Gouveia Brazao CA, Gillis AJ, van Roozendaal KE, van Zoelen EJ, Weber RF, Wolffenbuttel KP, van Dekken H, Honecker F, Bokemeyer C, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 2003;63:2244-50.
24. Hellerstedt BA, Pienta KJ. Germ cell tumors: review of selected studies from 2002. Curr Opin Oncol 2003;15:234-8.
25. Oliver RT. Germ cell cancer. Curr Opin Oncol 1999;11:236-41.
26. Palumbo C, van Roozendaal K, Gillis AJ, van Gurp RH, de Munnik H, Oosterhuis JW, van Zoelen EJ, Looijenga LH. Expression of the PDGF alpha-receptor 1.5 kb transcript. OCT-4, and c-KIT in human normal and malignant tissues. Implications for the early diagnosis of testicular germ cell tumours and for our understanding of regulatory mechanisms. J Pathol 2002;196:467-77.
27. Monk M, Holding C. Human embryonic genes re-expressed in cancer cells. Oncogene 2001;20:8085-91.
28. Wang P, Branch DR, Bali M, Schultz GA, Goss PE, Jin T. The POU homeodomain protein OCT3 as a potential transcriptional activator for fibroblast growth factor-4 (FGF-4) in human breast cancer cells. Biochem J 2003;375:199-205.
29. Jin T, Branch DR, Zhang X, Qi S, Youngson B, Goss PE. Examination of POU homeobox gene expression in human breast cancer cells. Int J Cancer 1999;81:104-12.
30. Hochedlinger K, Yamada Y, Beard C, Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005;121:465-77.
31. Sambrook J, Russell DW. Molecular cloning: a laboratory manual, 3 ed. New York: Cold Spring Harbor Laboratory Press, 2001.
32. Lee J, Kim HK, Han YM, Kim J. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int J Biochem Cell Biol 2008;40:1043-54.
33. Kim J, Lee JM, Branton PE, Pelletier J. Modification of EWS/WT1 functional properties by phosphorylation. Proc Natl Acad Sci USA 1999;96:14300-5.
34. Kim J, Lee JM, Branton PE, Pelletier J. Modulation of EWS/WT1 activity by the v-Src protein tyrosine kinase. FEBS Lett 2000;474:121-8.
35. Lee J, Kim HK, Rho JY, Han YM, Kim J. The human OCT-4 isoforms differ in their ability to confer self-renewal. J Biol Chem 2006;281:33554-65.
36. Nishimoto M, Fukushima A, Okuda A, Muramatsu M. The gene for the embryonic stem cell coactivator UTF1 carries a regulatory element which selectively interacts with a complex composed of Oct-3/4 and Sox-2. Mol Cell Biol 1999;19:5453-65.
37. Knoop LL, Baker SJ. The splicing factor U1C represses EWS/FLI-mediated transactivation. J Biol Chem 2000;275:24865-71.
38. Petermann R, Mossier BM, Aryee DN, Khazak V, Golemis EA, Kovar H. Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene 1998;17:603-10.
39. Ezashi T, Ghosh D, Roberts RM. Repression of Ets-2-induced transactivation of the tau interferon promoter by Oct-4. Mol Cell Biol 2001;21:7883-91.
40. Brehm A, Ohbo K, Zwerschke W, Botquin V, Jansen-Durr P, Scholer HR. Synergism with germ line transcription factor Oct-4: viral oncoproteins share the ability to mimic a stem cell-specific activity. Mol Cell Biol 1999;19:2635-43.
41. Vigano MA, Staudt LM. Transcriptional activation by Oct-3: evidence for a specific role of the POU-specific domain in mediating functional interaction with Oct-1. Nucleic Acids Res 1996;24:2112-8.
42. Ghosh A, Stewart D, Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 2004;24:7987-97.
43. Ptashne M. How eukaryotic transcriptional activators work. Nature 1988;335:683-9.
44. Levine M, Manley JL. Transcriptional repression of eukaryotic promoters. Cell 1989;59:405-8.
45. Herskowitz I. Functional inactivation of genes by dominant negative mutations. Nature 1987;329:219-22.
46. Calvo R, Drabkin HA. Embryonic genes in cancer. Ann Oncol 2000;11 (Suppl 3):207-18.
47. Tan Y, Timakhov RA, Rao M, Altomare DA, Xu J, Liu Z, Gao Q, Jhanwar SC, Di Cristofano A, Wiest DL, Knepper JE, Testa JR. A novel recurrent chromosomal inversion implicates the homeobox gene Dlx5 in T-cell lymphomas from Lck-Akt2 transgenic mice. Cancer Res 2008;68:1296-302.